Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
RD01
DRUG
2 trials
Sponsors
Shengzhen Sciprogen Bio-pharmaceutical Co. Ltd
Conditions
Healthy
Patient of Anemia in Chronic Renal Failure With Hemodialysis
Phase 1
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of RD01 (Pegerythropoietin) in Healthy Chinese Volunteers
Completed
NCT03657238
Shengzhen Sciprogen Bio-pharmaceutical Co. Ltd
Healthy
Start: 2018-04-08
End: 2019-08-02
Updated: 2020-03-16
Phase 2
A Phase 2 Clinical Study of Pegerythropoietin Injection (RD01) for the Treatment of Anemia in Chronic Renal Failure Patients With Hemodialysis
NCT04231292
Shengzhen Sciprogen Bio-pharmaceutical Co. Ltd
Patient of Anemia in Chronic Renal Failure With Hemodialysis
Start: 2020-03-01
End: 2022-12-31
Target: 105
Updated: 2020-01-18
Related Papers
A Phase I Dose-Escalation Study of The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Polyethylene Glycol-Erythropoietin (PEG-EPO) in Healthy Subjects
Clinical Therapeutics
2024-08-01
1 citations